Page 113 - Forbes - USA (December 2019)

PROMOTION
Nanopharmacia Group:
HEALTH INNOVATION FOR LATIN AMERICA
The World Health Organization proj-
ects that the number of new cases of dia-
betes and cancer in Latin America could
increase by more than 70% in the next
decade. Preventing and combatting these
diseases requires innovation and invest-
ment. The Mexican company Nanophar-
macia Group offers both.
The company is rising to the chal-
lenges of health care in Mexico and Latin
America. It is the only private company in
Latin America in the business of develop-
ing new therapeutic products using nano-
technology to treat diabetes and cancer.
Horacio Astudillo de la Vega, Nanopharmacia
lead scientist, founder and partner
“Diabetes is a metabolic disease that
has increased dramatically in Mexico in
the last 10 years, and cancer is a complex
disease closely linked to multiple factors
including metabolic and infectious,” says
Horacio Astudillo de la Vega, Nanophar-
macia lead scientist, founder and partner.
Nanopharmacia Group integrates
Nanopharmacia Diagnostica, a leader
in precision cancer medicine in Mexico;
Nanoclinic, a clinical laboratory diagnos-
tic firm; Healthcare Business and Com-
puter Technologies, which offers novel
supplement combinations and medical
device technologies; and DNI Genet-
ics & Nutrition, developer of genetic
metabolism diagnostics and personalized
PROMOTION
Editor in Chief Paul Trustfull
nutritional treatments. Each company is
already active commercially with prod-
ucts and services, using 100% Mexican-
owned scientific developments.
Nanopharmacia Group has evaluated
more than 40,000 cases in the last eight
years and serves patients with chronic
degenerative diseases at both public and
private institutions. Its private Nano-
pharmacia Foundation was established
to further provide research and support
for disease prevention and cures.
Improving Lives With Detection and
Advanced Treatments
“In Mexico, a national program for
timely detection has not been estab-
lished,” says Astudillo de la Vega. “Dia-
betes treatment and detection strate-
gies have not had a favorable impact on
disease control in our country. In Latin
America, the situation is no less serious,
as in Mexico, the high cost of medical
and pharmaceutical interventions is not
accessible to the entire population.” By
offering advanced early-detection and
diagnostic tools, Nanopharmacia hopes
to improve lives.
As it continues to innovate, the com-
pany is looking to expand the market for
its supplement products. Some of these
formulations, improved with the use of
nanotechnology, have been proven benefi-
cial for regulating the metabolic behavior
of complex diseases such as diabetes and
cancer. Some of Nanopharmacia’s supple-
ment formulations have been granted
patents in the United States, the EU
Nanopharmacia Laboratory Machine
and in more than 40 countries including
China, India and Russia. Many more are
in the pipeline.
Nanopharmacia’s product DIAKRONE
developed by Nanopharmacia has demon-
strated benefits for patients with diabetes
and diabetic complications. DIAKRONE
was approved by Mexico’s health and drug
regulatory agency COFEPRIS to start the
first study with diabetic patients, a step
toward the product’s approval.
“The global market for advanced
molecular diagnosis and supplements is
one of the fastest growing in the world,”
says Astudillo de la Vega. “It is estimated
that it will reach more than $16 billion by
2025, especially for products that offer
combinations with improved efficacy
based on the use of nanotechnology as we
are doing now. This segment of develop-
ment in pharmaceutical and scientific
innovation is undoubtedly the one with
the greatest acceleration in investment
for new businesses.”
Paul Trustfull and Horacio Astudillo de la Vega
Emerging Markets 1